Charles River Laboratories International, Inc.

CRL Healthcare · Diagnostics & Research
Delayed 15 min
Last close
$225.57
Jun 29, 2026
52-week range
$144.26 — $228.88
-1% from high
Market cap
10.9B
Diluted basis
Dividend yield
No dividend declared
P/E
Trailing
Filing.fyi verdict · Jun 29, 2026

Fairly valued.

Fairly Valued (Neutral) — Filing.fyi's reading derived from the latest 10-K and forensic scores.

Neutral
RED DEEP / 100
Composite Health
AI synthesis · grounded in this ticker's SEC filings · drag to highlight, releases the composer

What the filing actually says.

AI · wry-editorial preset

The most striking aspect of this Charles River Laboratories International, Inc. (CRL) reading is the absence of specific filing details and quantitative forensic metrics. Without a specified form type, filing date, or report period, the foundational context for a forensic analysis remains undefined. This initial data gap prevents the immediate application of quantitative scrutiny, shifting the focus to the implications of such informational scarcity.

The standard suite of forensic scores, typically a cornerstone of our analysis, is not available for CRL in this instance. This includes Beneish’s M-Score, a 1999 eight-ratio earnings-manipulation detector, which flags elevated risk above -1.78. Similarly, Altman’s Z″, a 1968 bankruptcy-distress index, which categorizes companies into distress (<1.10), grey (1.10–2.60), or safe (>2.60) zones, is absent. Piotroski’s F-Score, a 9-point fundamental strength scan, and the Fog Index, a readability score where 12 equals a newspaper and 18+ suggests obfuscation, are also not provided. The lack of these metrics means no quantitative signals regarding potential manipulation, distress, fundamental strength, or textual complexity can be derived from this reading.

The usual practice of examining specific risk factors from Item 1A or dwelling on passages from Item 7 (MD&A) is similarly constrained. No excerpts from either section were provided for this analysis. Consequently, insights into management’s discussion of operations, financial condition, or specific forward-looking risks, such as liquidity concerns or operational challenges, cannot be interpreted. This absence means the filing itself offers no direct textual evidence to contextualize any potential quantitative findings, which are themselves unavailable.

This reading, therefore, is limited to observing the lack of available data rather than interpreting it. It cannot inform whether the CRL security is mispriced, as that determination requires a comprehensive review of financial statements, operational disclosures, and market context, none of which are accessible through the provided information. The utility of this particular filing analysis lies primarily in highlighting the importance of complete and accessible data for forensic accounting scrutiny. Without the filing itself, or its summarized metrics, no substantive conclusions can be drawn about the company’s financial health or reporting transparency.

Member feature · Custom Q&A
Ask anything about CRL's filings.
Plain-English answer, cited from the company's own 10-K and recent 10-Qs. No buy/sell advice.
Ask a question →
Further reading · curated for this filing

If this case caught your eye

Affiliate links — Filing.fyi earns a commission on Amazon purchases. We pick the books first, attach the link second.

Financial Shenanigans

Howard M. Schilit

Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.

View on Amazon →

The Interpretation of Financial Statements

Benjamin Graham

The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.

View on Amazon →
Quality of Earnings

Quality of Earnings

Thornton L. O'glove

Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.

View on Amazon →